



Plenary sitting

B8-1432/2016

3.1.2017

MOTION FOR A RESOLUTION

pursuant to Rule 133 of the Rules of Procedure

on MCR-1 and colistin resistance

Mireille D'Ornano

Motion for a European Parliament resolution on MCR-1 and colistin resistance

The European Parliament,

- having regard to Article 168 of the Treaty on the Functioning of the European Union,
- having regard to Rule 133 of its Rules of Procedure,
- A. whereas colistin is a ‘critically important’ antibiotic (World Health Organisation) and colistin use doubled in the European Union between 2010 and 2014;
- B. whereas *Escherichia coli* bacteria in China have been found to contain the MCR-1 gene (**MCR-1**), making *Escherichia coli* resistant to colistin;
- C. whereas MCR-1, first identified in China, is now present on all five continents, and whereas a 2014 study of 2 001 Dutch citizens returning from travel abroad – none of whom had accessed medical care while away – found six to be carrying MCR-1;
- D. whereas a case of treatment failure was reported in Denmark in 2015;
- 1. Stresses that resistance to colistin is particularly alarming in view of the fact that it is used as a last-resort treatment and that MCR-1 is transmitted via plasmid;
- 2. Takes note of the evaluation of the European Centre for Disease Prevention and Control (**ECDC**) of 13 June 2016 and urges the Commission to step up its monitoring of MCR-1 via the ECDC.